Journal: Experimental and Therapeutic Medicine

Article Title: Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma

doi: 10.3892/etm.2021.9901

Figure Lengend Snippet: Protein expression of S100P and RAGE in patients with NPC or benign nasopharyngeal inflammation. (A) The protein expression of S100P and RAGE in NPC tissues and nasopharyngeal tissues with benign inflammation by western blotting. Quantification of (B) S100P/GAPDH and (C) RAGE/GAPDH protein expression ratios. * P<0.05 and *** P<0.001. RAGE, receptor for activated glycation end products; NPC, nasopharyngeal carcinoma.

Article Snippet: The following three groups of C666-1 cells were used in subsequent assays: The S100P protein group, treated with S100P (cat. no. Ag19115; Proteintech Group, Inc.), the FPS-ZM1 group, treated with the RAGE inhibitor FPS-ZM1 (cat. no. 6237; Tocris Bioscience) , and the untreated control group.

Techniques: Expressing, Western Blot

Journal: Experimental and Therapeutic Medicine

Article Title: Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma

doi: 10.3892/etm.2021.9901

Figure Lengend Snippet: Differences in S100P expression levels according to the disease stage, age and sex of patients.

Article Snippet: The following three groups of C666-1 cells were used in subsequent assays: The S100P protein group, treated with S100P (cat. no. Ag19115; Proteintech Group, Inc.), the FPS-ZM1 group, treated with the RAGE inhibitor FPS-ZM1 (cat. no. 6237; Tocris Bioscience) , and the untreated control group.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma

doi: 10.3892/etm.2021.9901

Figure Lengend Snippet: Effects of S100P and RAGE on the proliferation and colony formation of C666-1 cells. Cell Counting Kit-8 assay results for the growth evaluation of cells treated with (A) S100P protein or (B) RAGE inhibitor FPS-ZM1 at the indicated concentrations for 6 h. The effects of S100P and FPS-ZM1 on cell viability were concentration-dependent. (C) The effects of S100P protein and FPS-ZM1 (both 1,000 ng/ml) on cell viability were also time-dependent. (D) Representative images of colony formation assay results. (E) The colony forming ability of C666-1 cells was increased in the S100P protein group and reduced in the FPS-ZM1 group. ** P<0.01 and *** P<0.001 vs. untreated control. RAGE, receptor for activated glycation end products; OD450, optical density at 450 nm.

Article Snippet: The following three groups of C666-1 cells were used in subsequent assays: The S100P protein group, treated with S100P (cat. no. Ag19115; Proteintech Group, Inc.), the FPS-ZM1 group, treated with the RAGE inhibitor FPS-ZM1 (cat. no. 6237; Tocris Bioscience) , and the untreated control group.

Techniques: Cell Counting, Concentration Assay, Colony Assay, Control

Journal: Experimental and Therapeutic Medicine

Article Title: Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma

doi: 10.3892/etm.2021.9901

Figure Lengend Snippet: Effects of S100P and RAGE on C666-1 cell migration. (A) Representative images of the wound healing assay (magnification, x400). (B) Measurements of the wound in the cell monolayer revealed that wound closure was induced by treatment with S100P protein and delayed by treatment with the RAGE inhibitor FPS-ZM1 compared with the untreated control. (C) The percentage of wound closure was different in the S100P protein and FPS-ZM1 groups compared with the untreated control group. (D) Representative images of the Transwell assay results. Scale bar, 200 µm. (E) The Transwell assay revealed that the migration ability of C666-1 cells was significantly increased by S100P protein and significantly reduced by the RAGE inhibitor FPS-ZM1. RAGE, receptor for activated glycation end products. *** P<0.001.

Article Snippet: The following three groups of C666-1 cells were used in subsequent assays: The S100P protein group, treated with S100P (cat. no. Ag19115; Proteintech Group, Inc.), the FPS-ZM1 group, treated with the RAGE inhibitor FPS-ZM1 (cat. no. 6237; Tocris Bioscience) , and the untreated control group.

Techniques: Migration, Wound Healing Assay, Control, Transwell Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma

doi: 10.3892/etm.2021.9901

Figure Lengend Snippet: S100P-RAGE activates MAPK and NF-κB signaling in C666-1 cells. (A) Representative western blots of cells treated with S100P protein or RAGE inhibitor FPS-ZM1. (B) Quantified western blotting data showing that p-ERK1/2/ERK1/2, p-p38/p38 and p-MAPK7/MAPK7 ratios and NF-κB1 and p65 expression levels were significantly increased in the S100P protein group and significantly reduced in the FPS-ZM1 group compared with those in untreated cells. * P<0.05 and *** P<0.001. RAGE, receptor for activated glycation end products; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-related kinase.

Article Snippet: The following three groups of C666-1 cells were used in subsequent assays: The S100P protein group, treated with S100P (cat. no. Ag19115; Proteintech Group, Inc.), the FPS-ZM1 group, treated with the RAGE inhibitor FPS-ZM1 (cat. no. 6237; Tocris Bioscience) , and the untreated control group.

Techniques: Western Blot, Expressing

Journal: PLoS ONE

Article Title: Can Wound Exudate from Venous Leg Ulcers Measure Wound Pain Status?: A Pilot Study

doi: 10.1371/journal.pone.0167478

Figure Lengend Snippet: Wound and pain characteristics during each examination.

Article Snippet: S100A8/A9 concentrations were measured using a Human S100 Calcium-binding Protein A8/A9 Complex (S100A8/A9) ELISA Kit (Cusabio Biotech, Wuhan, China).

Techniques:

Journal: British Journal of Cancer

Article Title: Tissue biomarkers of breast cancer and their association with conventional pathologic features

doi: 10.1038/bjc.2012.552

Figure Lengend Snippet: Immunological validation of ubiquitin and S100P. ( A ) For ubiquitin, four BC and corresponding AT extracts were analysed by immunoblotting, indicating relative upregulation of ubiquitin in some breast cancer patients. β -Actin is shown as a loading control. ( B ) Densitometric analysis of ubiquitin western blots of eight sample pairs. Box plot shows median and upper and lower quartiles; lines show maximum and minimum values. P =0.017, Wilcoxon signed-rank test. ( C ) Mass spectrometry (MS) spectra of proteins bound to immobilised mouse anti-ubiquitin antibody. Samples were (i) patient 1 normal tissue, (ii) patient 1 cancer tissue, (iii) patient 2 normal tissue, (iv) patient 2 cancer tissue, (v) recombinant His-tagged ubiquitin, and (vi) patient 2 cancer tissue, mouse IgG control. Arrow indicates the mass of monomeric ubiquitin, m/z 8558. N=normal tissue; C=cancer tissue. ( D ) For S100P, four BC and corresponding AT extracts were analysed by immunoblotting, indicating relative upregulation of S100P in some breast cancer patients. β -Actin is shown as a loading control. ( E ) Densitometric analysis of S100P Western blots of 8 sample pairs. Box plot shows median and upper and lower quartiles; lines show maximum and minimum values. P =0.012, Wilcoxon signed-rank test. ( F ) Mass spectrometry spectra of proteins bound to immobilised rabbit anti-S100P antibody. Samples were (i) patient 3 normal tissue, (ii) patient 3 cancer tissue, (iii) patient 4 normal tissue, (iv) patient 4 cancer tissue, (v) recombinant His-tagged S100P, and (vi) patient 4 cancer tissue, rabbit IgG control. Arrow indicates the mass of the S100P form of m/z 9226. N=normal tissue; C=cancer tissue.

Article Snippet: His-tagged recombinant S100P (12.6 kDa; Novus Biologicals, Littleton, CO, USA) was used as a control.

Techniques: Biomarker Discovery, Ubiquitin Proteomics, Western Blot, Control, Mass Spectrometry, Recombinant

Journal: British Journal of Cancer

Article Title: Tissue biomarkers of breast cancer and their association with conventional pathologic features

doi: 10.1038/bjc.2012.552

Figure Lengend Snippet: Association of two protein markers and their combination with tumour histopathologic variables

Article Snippet: His-tagged recombinant S100P (12.6 kDa; Novus Biologicals, Littleton, CO, USA) was used as a control.

Techniques: Ubiquitin Proteomics

Journal: Molecular Metabolism

Article Title: Neurons undergo pathogenic metabolic reprogramming in models of familial ALS

doi: 10.1016/j.molmet.2022.101468

Figure Lengend Snippet: Key resources table.

Article Snippet: Rabbit polyclonal anti-S100 beta , LSBio , Cat.No. LS-C268728 RRID: AB_11143806.

Techniques: Virus, Binding Assay, Control, Sequencing, Expressing, Plasmid Preparation, Recombinant, Software